Diebold Nixdorf, Incorporated
DBD · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,618 | $1,863 | $1,625 | $1,611 |
| - Cash | $296 | $550 | $319 | $389 |
| + Debt | $1,047 | $1,357 | $2,610 | $2,293 |
| Enterprise Value | $2,369 | $2,670 | $3,916 | $3,514 |
| Revenue | $3,751 | $3,761 | $3,461 | $3,905 |
| % Growth | -0.2% | 8.7% | -11.4% | – |
| Gross Profit | $920 | $876 | $757 | $1,043 |
| % Margin | 24.5% | 23.3% | 21.9% | 26.7% |
| EBITDA | $335 | $275 | -$113 | $294 |
| % Margin | 8.9% | 7.3% | -3.3% | 7.5% |
| Net Income | -$17 | $1,376 | -$581 | -$79 |
| % Margin | -0.4% | 36.6% | -16.8% | -2% |
| EPS Diluted | -0.44 | 21.38 | -7.44 | -1 |
| % Growth | -102.1% | 387.4% | -644% | – |
| Operating Cash Flow | $149 | -$257 | -$388 | $123 |
| Capital Expenditures | -$17 | -$25 | -$53 | -$51 |
| Free Cash Flow | $132 | -$282 | -$441 | $72 |